After this date, the rosiglitazone products Avandia and Avandamet will no longer be available in the UK. GSK said that all patients should be switched onto alternative treatments before this date.
A statement from GSK said: ‘In agreement with the MHRA, we believe that a 28-day period from the date of the EMA recommendation will be adequate for patients to be reviewed and transitioned to alternative treatments.’
GPs are advised to review all patients on the drugs as soon as possible and before this deadline.
Prescribers should not issue new or repeat prescriptions of rosiglitazone-containing medicines, said GSK.
